Projects per year
Personal profile
Personal profile
Dr. Lu is a researcher working in the fields including but not limited to nanomedicine, drug delivery and tumor intervention. He finished his bachelor study in pharmacy in Anhui medical university and master in Industrial pharmaceutical sciences in Brighton university (UK). Later, he worked on smart liposome-based drug delivery for tumor treatment in the phd study at Erasmus Medical Center (NL), followed by a post doc training for tumor manipulation and CTCCAF detection at Twente university (NL). In 2021, he joined in Chinese academy of sciences (Shanghai) as an associate researcher working on gene editing technology. At the end of 2023, Dr. Lu joined XJTLU wisdom lake academy of pharmacy as an assistant professor. He can be reached by email (Tao.Lu@xjtlu.edu.cn) if you are interested in collaboration with him.
Research interests
development of oral preparations with high bioavailability and other advanced formulations
tumor intervention with chemotherapy and/or gene therapy technology
development of novel, smart biomaterials and pharmaceutical excipient materials for drug delivery
Experience
Assistant professor, Wisdom Lake Academy of Pharmacy, XJTLU, 2023-present
Associate researcher, CEBSIT, Chinese Academy of Sciences, 2021-2023
Post doc, Twente university, 2019-2021
Assistant researcher,Anhui University of Chinese Medicine, 2013-2014
Researcher assistant, Lifeon Pharmaceutcical Co.Ltd, 2013
Teaching
module leader of APH407, APH213
Education/Academic qualification
PhD, Erasmus University Medical Center, 2018
Person Types
- Staff
Fingerprint
Dive into the research topics where Tao Lu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
hepatic stellate cell targed lipid based delivery system development for fiborsis intervention
1/07/24 → 30/06/26
Project: Internal Research Project
-
National Natural Science Foundation of China—Youth Science Fund.
1/05/23 → 31/12/25
Project: Governmental Research Project
-
Downregulation of Ripk1 and Nsf mediated by CRISPR-CasRx ameliorates stroke volume and neurological deficits after ischemia stroke in mice
Song, X., Lan, Y., Lv, S., Wang, Y., Chen, L., Lu, T., Liu, F. & Peng, D., 11 Jun 2024, In: Frontiers in Aging Neuroscience. 16Research output: Contribution to journal › Article › peer-review
-
Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool
Li, T., Zhang, L., Lu, T., Zhu, T., Feng, C., Gao, N., Liu, F., Yu, J., Chen, K., Zhong, J., Tang, Q., Zhang, Q., Deng, X., Ren, J., Zeng, J., Zhou, H. & Zhu, J., 5 Apr 2023, In: Advanced Science. 10, 10, 2206517.Research output: Contribution to journal › Article › peer-review
Open Access11 Citations (Scopus) -
In Vivo Detection of Circulating Cancer-Associated Fibroblasts in Breast Tumor Mouse Xenograft: Impact of Tumor Stroma and Chemotherapy
Lu, T., Oomens, L., Terstappen, L. W. M. M. & Prakash, J., Feb 2023, In: Cancers. 15, 4, 1127.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
MicroRNA in the tumor stroma: diagnostic and therapeutic implications
Lu, T., Terstappen, L. & Prakash, J., 2022, The Tumor Stroma. Jenny Stanford PublishingResearch output: Chapter in Book or Report/Conference proceeding › Chapter › peer-review
-
Externally triggered smart drug delivery system encapsulating idarubicin shows superior kinetics and enhances tumoral drug uptake and response
Lu, T., Haemmerich, D., Liu, H., Seynhaeve, A. L. B., van Rhoon, G. C., Houtsmuller, A. B. & ten Hagen, T. L. M., 2021, In: Theranostics. 11, 12, p. 5700-5712 13 p.Research output: Contribution to journal › Article › peer-review
Open Access18 Citations (Scopus)